CoChat

EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells

Open access
Mallmann-Gottschalk, Nina, Sax, Yvonne, Kimmig, Rainer, Lang, Stephan, Brandau, Sven · 2019 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

The adverse prognosis of most patients with ovarian cancer is related to recurrent disease caused by resistance to chemotherapeutic and targeted therapeutics. Besides their direct activity against tumor cells, monoclonal antibodies and tyrosine kinase inhibitors (TKIs) also influence the antitumoral activity of immune cells, which has important implications for the design of immunotherapies. In this preclinical study, we treated different ovarian cancer cell lines with anti-epidermal growth factor receptor (EGFR) TKIs and co-incubated them with natural killer (NK) cells. We studied treatment-related structural and functional changes on tumor and immune cells in the presence of the anti-EGFR antibody cetuximab and investigated NK-mediated antitumoral activity. We show that long-term exposure of ovarian cancer cells to TKIs leads to reduced responsiveness of intrinsically sensitive cancer cells over time. Inversely, neither long-term treatment with TKIs nor cetuximab could overcome the intrinsic resistance of certain ovarian cancer cells to anti-EGFR agents. Remarkably, tumor cells pretreated with anti-EGFR TKIs showed increased sensitivity towards NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). In contrast, the cytokine secretion of NK cells was reduced by TKI sensitization. Our data suggest that sensitization of tumor cells by anti-EGFR TKIs differentially modulates interactions with NK cells. These data have important implications for the design of chemo-immuno combination therapies in this tumor entity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20194693

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of sensitization with anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on ovarian cancer cell viability and antiproliferative activity of cetuximab (Cet). Cell viability (%) of (a) IGROV-1 and (d) SKOV-3 after short-term treatment (72 h) with erlotinib (E), gefitinib (G), and vandetanib (V) is shown in white columns. Striped columns indicate addition of cetuximab. Cell viability was assessed by performing MTT assay. (b,c,e,f): Cell viability of (b+c) IGROV-1 and (e+f) SKOV-3 sensitized with erlotinib (sE), gefitinib (sG), and vandetanib (sV) (1 µM) for 7 days and 6 weeks, respectively. White columns illustrate cell viability under continuous anti-EGFR treatment, grey columns document cell viability 72 h after discontinuation of TKI treatment. Striped columns show addition of cetuximab. Bars show means +/- standard deviation (SD) of four to six independent experiments. For illustration purposes, the cell viability of treated and sensitized cells is shown in relation to untreated and unsensitized tumor cells (w/o) in (a) and (d). Unpaired t-test was applied for statistical analysis, statistical significance (p < 0.05) is indicated (*).
Figure 1 Effects of sensitization with anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on ovarian cancer cell viability and antiproliferative activity of cetuximab (Cet). Cell viability (%) of (a) IGROV-1 and (d) SKOV-3 after short-term treatment (72 h) with erlotinib (E), gefitinib (G), and vandetanib (V) is shown in white columns. Striped columns indicate addition of cetuximab. Cell viability was assessed by performing MTT assay. (b,c,e,f): Cell viability of (b+c) IGROV-1 and (e+f) SKOV-3 sensitized with erlotinib (sE), gefitinib (sG), and vandetanib (sV) (1 µM) for 7 days and 6 weeks, respectively. White columns illustrate cell viability under continuous anti-EGFR treatment, grey columns document cell viability 72 h after discontinuation of TKI treatment. Striped columns show addition of cetuximab. Bars show means +/- standard deviation (SD) of four to six independent experiments. For illustration purposes, the cell viability of treated and sensitized cells is shown in relation to untreated and unsensitized tumor cells (w/o) in (a) and (d). Unpaired t-test was applied for statistical analysis, statistical significance (p < 0.05) is indicated (*).CC BY · PubMed Central
Figure 2 Sensitivity of anti-EGFR TKI sensitized ovarian cancer cells to FasLigand, TRAIL, NK-mediated cytotoxic degranulation, and NK cell-related lysis. Percentage of apoptotic cells (%) of erlotinib-sensitized IGROV-1 cells (7 days) and unsensitized controls after exposure to (a) FasLigand (FasL) and (b) TRAIL for 24 h in increasing concentrations up to 100 ng/mL. Analysis per FACS after performing Annexin-V Apoptosis Detection Kit. (c)–(f): Anti-EGFR-TKI sensitization of IGROV-1 for 7 days and SKOV-3 for 6 weeks. Co-incubation (1:1 cell ratio) with NK cells isolated from healthy donors with or without cetuximab (1 µg/mL). (c) + (e): NK cell-mediated cytotoxic degranulation: CD107a-positive NK cells (%) after performing CD107a degranulation assay and analyzing per FACS. (d) + (f): NK-specific tumor cell lysis. Tumor cell viability (%) as difference between vital and apoptotic cells in relation to unsensitized controls (= 100%) after performing Annexin-V Apoptosis Detection Kit and analyzing in the flow cytometer. Means +/- SD of at least three independent experiments are shown. Statistical analysis was performed by unpaired t-test, statistical significance (p < 0.05) is indicated (*). (g) Plots of the percentage of CD107a-positive NK cells in the presence of unsensitized IGROV-1 cells without (w/o) or with cetuximab (w/o + Cet) and in the presence of erlotinib-sensitized IGROV-1 cells (7 days) and cetuximab (sE + Cet). A representative experiment is shown.
Figure 2 Sensitivity of anti-EGFR TKI sensitized ovarian cancer cells to FasLigand, TRAIL, NK-mediated cytotoxic degranulation, and NK cell-related lysis. Percentage of apoptotic cells (%) of erlotinib-sensitized IGROV-1 cells (7 days) and unsensitized controls after exposure to (a) FasLigand (FasL) and (b) TRAIL for 24 h in increasing concentrations up to 100 ng/mL. Analysis per FACS after performing Annexin-V Apoptosis Detection Kit. (c)–(f): Anti-EGFR-TKI sensitization of IGROV-1 for 7 days and SKOV-3 for 6 weeks. Co-incubation (1:1 cell ratio) with NK cells isolated from healthy donors with or without cetuximab (1 µg/mL). (c) + (e): NK cell-mediated cytotoxic degranulation: CD107a-positive NK cells (%) after performing CD107a degranulation assay and analyzing per FACS. (d) + (f): NK-specific tumor cell lysis. Tumor cell viability (%) as difference between vital and apoptotic cells in relation to unsensitized controls (= 100%) after performing Annexin-V Apoptosis Detection Kit and analyzing in the flow cytometer. Means +/- SD of at least three independent experiments are shown. Statistical analysis was performed by unpaired t-test, statistical significance (p < 0.05) is indicated (*). (g) Plots of the percentage of CD107a-positive NK cells in the presence of unsensitized IGROV-1 cells without (w/o) or with cetuximab (w/o + Cet) and in the presence of erlotinib-sensitized IGROV-1 cells (7 days) and cetuximab (sE + Cet). A representative experiment is shown.CC BY · PubMed Central
Figure 3 IFNγ production and release of NK cells in the presence of erlotinib-sensitized IGROV-1 cells. NK cells of healthy donors were co-incubated in a 1:1 cell ratio with erlotinib-sensitized IGROV-1 cells (7 days) with or without cetuximab (1 µg/mL). (a) Intracellularly IFNγ-positive NK cells (%) after APC-coupled anti-IFNγ staining or isotype control and analysis per FACS. (b) IFNγ release out of NK cells was quantified via ELISpot. IL15/IL18-stimulated NK cells served as positive controls. Means +/- SD of at least three independent experiments are shown. Statistical analysis was performed by unpaired t-test, statistical significance (p < 0.05) is indicated (*). (c) Plots of the percentage (%) of IFNγ-positive NK cells in the presence of unsensitized IGROV-1 cells without (w/o) or with cetuximab (w/o + Cet) and in the presence of erlotinib-sensitized IGROV-1 cells (7 days) and cetuximab (sE + Cet). A representative experiment is shown.
Figure 3 IFNγ production and release of NK cells in the presence of erlotinib-sensitized IGROV-1 cells. NK cells of healthy donors were co-incubated in a 1:1 cell ratio with erlotinib-sensitized IGROV-1 cells (7 days) with or without cetuximab (1 µg/mL). (a) Intracellularly IFNγ-positive NK cells (%) after APC-coupled anti-IFNγ staining or isotype control and analysis per FACS. (b) IFNγ release out of NK cells was quantified via ELISpot. IL15/IL18-stimulated NK cells served as positive controls. Means +/- SD of at least three independent experiments are shown. Statistical analysis was performed by unpaired t-test, statistical significance (p < 0.05) is indicated (*). (c) Plots of the percentage (%) of IFNγ-positive NK cells in the presence of unsensitized IGROV-1 cells without (w/o) or with cetuximab (w/o + Cet) and in the presence of erlotinib-sensitized IGROV-1 cells (7 days) and cetuximab (sE + Cet). A representative experiment is shown.CC BY · PubMed Central
Figure 4 Expression of MHC class I polypeptide-related sequence A, B (MICA, MICB) and MHC I on erlotinib-sensitized ovarian cancer cells. IGROV-1 and SKOV-3 were sensitized with erlotinib (1 µM) for 7 days and 6 weeks. Treated cells and unsensitized controls were stained with anti-MICA/anti-MICB and secondary antibody IgG1-PE and anti-HLA-class I-RPE and isotype controls, respectively. Analysis per FACS. ∆-MFI values show the difference of MFI between specific antibody and isotype control. (a) + (b): Expression of MICA. (c) + (d): Expression of MICB. (e) + (f): Expression of MHC I. Means +/- SD of at least three independent experiments are shown. Statistical analysis was performed by unpaired t-test, statistical significance (p < 0.05) is indicated (*). (g) Histogram: erlotinib-sensitized IGROV-1 (7 days) (blue line) or unsensitized controls (black line) were stained with anti-MICA/anti-MICB and secondary IgG1-PE or anti-HLA-class I-RPE, respectively, or isotype control (filled histogram). MFI of a representative experiment is shown.
Figure 4 Expression of MHC class I polypeptide-related sequence A, B (MICA, MICB) and MHC I on erlotinib-sensitized ovarian cancer cells. IGROV-1 and SKOV-3 were sensitized with erlotinib (1 µM) for 7 days and 6 weeks. Treated cells and unsensitized controls were stained with anti-MICA/anti-MICB and secondary antibody IgG1-PE and anti-HLA-class I-RPE and isotype controls, respectively. Analysis per FACS. ∆-MFI values show the difference of MFI between specific antibody and isotype control. (a) + (b): Expression of MICA. (c) + (d): Expression of MICB. (e) + (f): Expression of MHC I. Means +/- SD of at least three independent experiments are shown. Statistical analysis was performed by unpaired t-test, statistical significance (p < 0.05) is indicated (*). (g) Histogram: erlotinib-sensitized IGROV-1 (7 days) (blue line) or unsensitized controls (black line) were stained with anti-MICA/anti-MICB and secondary IgG1-PE or anti-HLA-class I-RPE, respectively, or isotype control (filled histogram). MFI of a representative experiment is shown.CC BY · PubMed Central
Figure 5 Secretion of IL18 of erlotinib-sensitized IGROV-1 cells. IGROV-1 cells were sensitized with erlotinib (1 µM) for 7 days. Secretion of IL18 of sensitized cells and untreated controls was quantified in the supernatants by ELISA. Bars show IL18 in pg/mL per 106 tumor cells. Means +/- SD of three independent experiments are shown. Statistical analysis was performed by unpaired t-test, statistical significance (p < 0.05) is indicated (*).
Figure 5 Secretion of IL18 of erlotinib-sensitized IGROV-1 cells. IGROV-1 cells were sensitized with erlotinib (1 µM) for 7 days. Secretion of IL18 of sensitized cells and untreated controls was quantified in the supernatants by ELISA. Bars show IL18 in pg/mL per 106 tumor cells. Means +/- SD of three independent experiments are shown. Statistical analysis was performed by unpaired t-test, statistical significance (p < 0.05) is indicated (*).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 34

Metadata

Authors
Mallmann-Gottschalk, N., Sax, Y., Kimmig, R., Lang, S., & Brandau, S.
Affiliations
  • Department of Gynecology and Obstetrics, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany
  • University of Duisburg-Essen (DE)
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-09-22
Volume
20
Issue
19
Pages
4693
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2973955555
Cited by
31
References
50
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 7
FWCI
1.90
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Deutsche Forschungsgemeinschaft
  • Universität Duisburg-Essen
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
ovarian cancer, EGFR tyrosine kinase inhibitors, cetuximab, natural killer cells, NK cell cytotoxicity, antibody-dependent cellular cytotoxicity, anti-EGFR antibody resistance, tumor sensitization, immunotherapy
MeSH terms
Antineoplastic Agents, Immunological, Antibody-Dependent Cell Cytotoxicity, Cell Survival, Cytotoxicity, Immunologic, Female, Humans, Killer Cells, Natural, Ligands, Ovarian Neoplasms, Biomarkers, Cytokines, Cell Line, Tumor, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.